Australia's premier life sciences investment conference, AusBiotech Invest 2025, opens today, welcoming investors, innovators, and global partners to connect with some of Australia's most investable biotechnology and medical technology companies.
Australia's life sciences industry is at a pivotal point, demonstrating credible deal flow, strong momentum in commercialisation, and an increasing rate of global partnerships.
Today, Australia's ecosystem is home to nearly 1,600 biotech and medtech companies – double the number of just eight years ago. The sector employs one in 60 jobs in Australia, and a market capitalisation of ASX-listed companies that has surged fivefold from $50 billion in 2017 to around $250 billion today.
"AusBiotech Invest continues to evolve as a strategic platform to connect capital with innovation," said Kerri Lee Sinclair, Head of Investment, AusBiotech.
"The calibre of investors and companies participating this year reflects the maturity of Australia's life sciences sector. We're not just seeing promising science. We're seeing repeatable commercial success and globally significant deal flow."
AusBiotech Invest welcomed close to 300 delegates to view presentations featuring 23 innovative private and listed Australian biotech companies, representing a significant opportunity for investors and potential partners to connect directly with companies seeking funding and collaborative development.
Presenting companies include; Amplia Therapeutics Ltd (ASX: ATX), Arovella Therapeutics (ASX: ALA) Avecho Biotechnology (ASX: AVE), BiomeBank, BlinkLab Ltd (ASX: BB1), Chimeric Therapeutics (ASX: CHM), Exosome Biosciences, Filamon, Goliver Australia Pty, Haemalogix Ltd, Humble Bee Bio Pty, Immuron Ltd (ASX: IMC), Invion, ISOBiotech, MLS Bio, Myopharm Limited, Neuroscientific Biopharmaceuticals (ASX:NSB), Polyactiva Pty Ltd, Prescient Therapeutics Ltd (ASX: PTX), QBiotics Group Ltd, S2n.bio, Terra Australis Pharmaceuticals Pty Ltd and Tiba Biotech.
Program highlights
The 2025 program delivers thought leadership from local and global investment leaders, in-depth discussions on capital formation, and insights into emerging technologies driving the next phase of biotech growth.
Opening Session: Megan Hooton, President, IQVIA Biotech, and Sarah Meibusch, Partner, OneVentures discussing how global trends, data-driven strategy, and AI are redefining clinical success. The session will provide actionable insights for investors and biotech executives seeking to improve trial efficiency and asset performance across development stages.
Panel Discussion: 'Building Australia's Future Life Sciences Capital Stack – Repeatable Success Stories' featuring Medard Fischer, VP Strategic Investments, Cochlear R&D; Rowena Gracey, Director, ARCHIMED; Sarah Meibusch, Partner, OneVentures; Chris Nave, Founding Partner & Managing Director, Brandon Capital; Aaron Ray, Managing Partner, 5 Horizons Ventures, and Kerri Lee Sinclair, Head of Investment, AusBiotech, unpacking the ingredients of sustainable investment success and examines how Australia can strengthen its capital stack to support global growth.
Keynote: Biotech Breakthroughs: ASX Market Performance and Insights with Blair Harrison, Head of Listings – New Zealand, ASX. A deep dive into the market dynamics and trends shaping ASX-listed biotech performance, investor sentiment, and global competitiveness.
Keynote: Global venture capitalist Nick Pachuda shares how Australia can build global life sciences leaders locally, adapting proven international models to deepen its capital base.
